Eva Ellebæk

2.8k total citations
71 papers, 1.6k citations indexed

About

Eva Ellebæk is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eva Ellebæk has authored 71 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 37 papers in Immunology and 22 papers in Molecular Biology. Recurrent topics in Eva Ellebæk's work include Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (36 papers) and Immunotherapy and Immune Responses (34 papers). Eva Ellebæk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), CAR-T cell therapy research (36 papers) and Immunotherapy and Immune Responses (34 papers). Eva Ellebæk collaborates with scholars based in Denmark, Italy and Germany. Eva Ellebæk's co-authors include Inge Marie Svane, Marco Donia, Mads Hald Andersen, Per thor Straten, Trine Zeeberg Iversen, Rikke Andersen, Özcan Met, Niels Junker, Troels Holz Borch and Lotte Engell-Noerregaard and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eva Ellebæk

65 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Ellebæk Denmark	21	1.2k	1.0k	392	146	94	71	1.6k
Husain Sattar United States	11	530 0.4×	784 0.8×	328 0.8×	256 1.8×	136 1.4×	26	1.5k
Satdip Kaur United Kingdom	7	845 0.7×	1.3k 1.3×	221 0.6×	140 1.0×	74 0.8×	10	1.9k
Anna Kwilas United States	16	587 0.5×	457 0.5×	240 0.6×	95 0.7×	246 2.6×	24	969
Hannah M. Knochelmann United States	14	649 0.5×	542 0.5×	288 0.7×	82 0.6×	126 1.3×	28	1.1k
Malin S. Nilsson Sweden	9	1.4k 1.1×	1.1k 1.1×	306 0.8×	52 0.4×	189 2.0×	17	1.9k
Daniela Samaniego‐Castruita United States	9	676 0.6×	972 1.0×	496 1.3×	103 0.7×	53 0.6×	12	1.5k
Xian-Yang Li China	21	565 0.5×	695 0.7×	358 0.9×	29 0.2×	60 0.6×	37	1.3k
Kyle K. Payne United States	22	699 0.6×	765 0.8×	544 1.4×	105 0.7×	120 1.3×	42	1.5k
Lars A. Ormandy Germany	9	1.2k 1.0×	1.8k 1.8×	329 0.8×	61 0.4×	100 1.1×	10	2.3k
Dennis O. Adeegbe United States	18	845 0.7×	1.2k 1.2×	487 1.2×	91 0.6×	232 2.5×	31	1.9k

Countries citing papers authored by Eva Ellebæk

Since Specialization

Citations

This map shows the geographic impact of Eva Ellebæk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Ellebæk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Ellebæk more than expected).

Fields of papers citing papers by Eva Ellebæk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Ellebæk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Ellebæk. The network helps show where Eva Ellebæk may publish in the future.

Co-authorship network of co-authors of Eva Ellebæk

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Ellebæk. A scholar is included among the top collaborators of Eva Ellebæk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Ellebæk. Eva Ellebæk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borch, Troels Holz, et al.. (2025). Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report. Melanoma Research. 35(5). 344–346.

Donia, Marco, Henrik Jespersen, Mathilde Jalving, et al.. (2025). Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028. ESMO Open. 10(3). 104295–104295. 2 indexed citations

Ellebæk, Eva, Marco Donia, & Inge Marie Svane. (2025). Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers. European Journal of Cancer. 217. 115257–115257. 1 indexed citations

Borch, Troels Holz, Rikke Andersen, Helle Westergren Hendel, et al.. (2025). Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes. Journal for ImmunoTherapy of Cancer. 13(2). e010575–e010575. 1 indexed citations

Holmstroem, Rikke B., Ane Teisner, Saeed Khan, et al.. (2024). 1138P A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters. Annals of Oncology. 35. S746–S747.

Weichenthal, Michael, Inge Marie Svane, Johanna Mangana, et al.. (2024). Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment. SHILAP Revista de lepidopterología. 2. 100271–100271. 1 indexed citations

Benzon, Eric von, Carsten Faber, Steen F. Urbak, et al.. (2024). Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study. Cancers. 16(19). 3346–3346. 5 indexed citations

Brink, Carsten, Thomas Heiberg Brix, Eva Ellebæk, et al.. (2024). Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study. Supportive Care in Cancer. 32(5). 281–281. 1 indexed citations

Hansen, Christian Rønn, Eva Ellebæk, Henrik Schmidt, et al.. (2024). Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study. European Journal of Cancer. 205. 114099–114099. 3 indexed citations

10.

Mapendano, Christophe K., Christina H. Ruhlmann, Inge Marie Svane, et al.. (2024). Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort. Cancers. 16(14). 2559–2559. 1 indexed citations

11.

Haslund, Charlotte Aaquist, Henrik Schmidt, Lars Bastholt, et al.. (2023). Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies. European Journal of Cancer. 195. 113392–113392. 6 indexed citations

12.

Ellebæk, Eva, Rikke B. Holmstroem, Marco Donia, et al.. (2023). 1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome. Annals of Oncology. 34. S690–S690. 3 indexed citations

13.

Svane, Inge Marie, et al.. (2023). 66MO Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes. Immuno-Oncology Technology. 20. 100538–100538. 1 indexed citations

14.

Chakera, Annette H., Helle Westergren Hendel, Eva Ellebæk, et al.. (2023). Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients. Annals of Surgical Oncology. 30(4). 2377–2388. 5 indexed citations

15.

Ellebæk, Eva, Shawez Khan, Lars Bastholt, et al.. (2023). PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. European Journal of Cancer. 198. 113476–113476. 18 indexed citations

16.

Bastholt, Lars, Inge Marie Svane, Marco Donia, et al.. (2021). Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers. 13(21). 5550–5550. 3 indexed citations

17.

Kjeldsen, Julie Westerlin, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.. (2021). A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine. 27(12). 2212–2223. 135 indexed citations

18.

Andersen, Rikke, Marco Donia, Eva Ellebæk, et al.. (2016). Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research. 22(15). 3734–3745. 234 indexed citations

19.

Iversen, Trine Zeeberg, Lotte Engell-Noerregaard, Eva Ellebæk, et al.. (2013). Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research. 20(1). 221–232. 100 indexed citations

20.

Andersen, Rikke, Charlotte Albæk Thrue, Niels Junker, et al.. (2012). Dissection of T-cell Antigen Specificity in Human Melanoma. Cancer Research. 72(7). 1642–1650. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact